Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

NCT02310867 | Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: Pro00056079
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test. Study activities include several study visits over 18 months and include; demographics, medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have loss of limb will be included in study evaluation. Risks of the study include risk of rejection and infection after being transplanted. Additional risk are associated with procedures that include blood draws, biopsies, x-rays, and potential loss of confidentiality. All patient data will be kept electronically and in accordance with the requirements of Duke University. In addition to the experimental data, this database includes recipient and donor demographics and transplant relevant medical history, range of motion, sensation, and immunosuppressive medications. Data will be recorded and reported in accordance with the standards required by the United Network for Organ Sharing (UNOS).

Conditions

Immunosuppression

Keywords

hand transplantation, amputation

Outcome Measures

Primary Outcomes (1)

• Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.

  18 months

Secondary Outcomes (2)

• Clinical rejection

  18 months

• Histological rejection

  18 months

Study Arms (1)

Hand transplant with Belatacept

EXPERIMENTAL

Drug: Belatacept; Procedure: Hand transplant

Interventions

Belatacept DRUG

This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.

Also known as: Nulojix

Hand transplant with Belatacept

Hand transplant PROCEDURE

The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.

Hand transplant with Belatacept

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients from 18-65 years old with loss of limb
• Willingness and legal ability to give informed consent
• Willingness to travel to study site for protocol specific samples to be taken, or in some cases, the ability to send samples via overnight mail

You may not qualify if:

• Any condition that precludes serial follow-up
• Any condition that would likely increase the risk of protocol participation or confound the interpretation of the data
• Any active malignancy or any history of a malignancy or lymphoma
• Inability or unwillingness to comply with protocol monitoring and therapy and immunodeficiency syndrome(s)

Sponsors & Collaborators

• Linda Cendales: lead

Study Sites (1)

Duke University Medical Center

Durham, North Carolina, 27710, United States

RECRUITING

MeSH Terms

Interventions

Abatacept

Intervention Hierarchy (Ancestors)

Immunoconjugates; Antibodies; Immunoglobulins; Serum Globulins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Globulins

Study Officials

• Linda Cendales, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Linda Cendales, MD

CONTACT

919-681-7514; linda.cendales@duke.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor of Surgery

Study Record Dates

• First Submitted: December 4, 2014
• First Posted: December 8, 2014
• Study Start: March 1, 2015
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): June 1, 2028
• Last Updated: April 9, 2026

Record last verified: 2026-04

Locations

US (1)